Cost of and payment source for pelvic inflammatory disease. Trends and projections, 1983 through 2000

A. E. Washington and P. Katz
Center for Reproductive Health Policy Research, School of Medicine, University of California, San Francisco 94109.

Pelvic inflammatory disease (PID) and its sequelae affect millions of women in the United States at substantial costs. To estimate these total costs annually and to determine payment sources, we analyzed data from local, state, and national sources. Direct costs for PID and PID-associated ectopic pregnancy and infertility were estimated to be $2.7 billion, and indirect costs were estimated to be $1.5 billion, for a total cost of $4.2 billion in 1990. Overall, private insurance covered the largest portion of the direct costs of PID (41%), followed by public payment sources (30%). However, the proportion of payments made by private insurance appears to be decreasing, while that by public payment sources is increasing. In the year 2000, costs associated with PID are projected to approach $10 billion if the current PID incidence persists, with an increasing proportion of this expense burdening public institutions. Prevention of PID is needed both to reduce human suffering and to contain rising costs.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Low Rates of Both Asymptomatic Chlamydia Screening and Diagnostic Testing of Women in U.S. Outpatient Clinics
Hoover et al.
Obstet Gynecol 2008;112:891-898.
ABSTRACT | FULL TEXT  

Missed Opportunities for Chlamydia Screening of Young Women in the United States
Hoover and Tao
Obstet Gynecol 2008;111:1097-1102.
ABSTRACT | FULL TEXT  

Chlamydia Heat Shock Protein 60 Induces Trophoblast Apoptosis through TLR4
Equils et al.
J. Immunol. 2006;177:1257-1263.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Screening Strategies for Gonorrhea Among Females in Private Sector Care.
Bernstein et al.
Obstet Gynecol 2006;107:813-821.
ABSTRACT | FULL TEXT  

Hospitalizations for pelvic inflammatory disease and tuboovarian abscess.
Paik et al.
Obstet Gynecol 2006;107:611-616.
ABSTRACT | FULL TEXT  

Screening for Chlamydia trachomatis in Women 15 to 29 Years of Age: A Cost-Effectiveness Analysis
Hu et al.
ANN INTERN MED 2004;141:501-513.
ABSTRACT | FULL TEXT  

Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes--implications for cost-effectiveness analyses
van Valkengoed et al.
Int J Epidemiol 2004;33:416-425.
ABSTRACT | FULL TEXT  

Vaginal Douching: Evidence for Risks or Benefits to Women's Health
Martino and Vermund
Epidemiol Rev 2002;24:109-124.
FULL TEXT  

Gang Involvement and the Health of African American Female Adolescents
Wingood et al.
Pediatrics 2002;110:e57-57.
ABSTRACT | FULL TEXT  

Evaluation of the Digene Hybrid Capture II Assay with the Rapid Capture System for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae
Van Der Pol et al.
J. Clin. Microbiol. 2002;40:3558-3564.
ABSTRACT | FULL TEXT  

Comparison of Digene Hybrid Capture 2 and Conventional Culture for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Cervical Specimens
Darwin et al.
J. Clin. Microbiol. 2002;40:641-644.
ABSTRACT | FULL TEXT  

Immunization with the Chlamydia trachomatis Mouse Pneumonitis Major Outer Membrane Protein Can Elicit a Protective Immune Response against a Genital Challenge
Pal et al.
Infect. Immun. 2001;69:6240-6247.
ABSTRACT | FULL TEXT  

Economic Evaluation of Safer Choices: A School-Based Human Immunodeficiency Virus, Other Sexually Transmitted Diseases, and Pregnancy Prevention Program
Wang et al.
Arch Pediatr Adolesc Med 2000;154:1017-1024.
ABSTRACT | FULL TEXT  

Direct Medical Cost of Pelvic Inflammatory Disease and Its Sequelae: Decreasing, but Still Substantial
REIN et al.
Obstet Gynecol 2000;95:397-402.
ABSTRACT | FULL TEXT  

Is the Routine Pelvic Examination Needed With the Advent of Urine-Based Screening for Sexually Transmitted Diseases?
Shafer et al.
Arch Pediatr Adolesc Med 1999;153:119-125.
ABSTRACT | FULL TEXT  

Chlamydia trachomatis Infections in Female Military Recruits
Gaydos et al.
NEJM 1998;339:739-744.
ABSTRACT | FULL TEXT  

Comparison of performance and cost-effectiveness of direct fluorescent- antibody, ligase chain reaction, and PCR assays for verification of chlamydial enzyme immunoassay results for populations with a low to moderate prevalence of Chlamydia trachomatis infection [In Process Citation]
Dean et al.
J. Clin. Microbiol. 1998;36:94-99.
ABSTRACT | FULL TEXT  

Doxycycline Compared with Azithromycin for Treating Women with Genital Chlamydia trachomatis Infections: An Incremental Cost-Effectiveness Analysis
Magid et al.
ANN INTERN MED 1996;124:389-399.
ABSTRACT | FULL TEXT  

Pelvic Inflammatory Disease
McCormack
NEJM 1994;330:115-119.
FULL TEXT  

PID: NEW FINDINGS ON A GROWING PROBLEM
JWatch General 1991;1991:9-9.
FULL TEXT